Offerings // Lantern Pharma Inc.

LTRN offering history

Every offering-related filing in Lantern Pharma Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 251 filings back to Jan 14, 2019.

Last executed offering

May 14, 2026

424B5 — priced deal (shares or notes)

Last registration (announced)

Jun 12, 2026

S-1 — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Jun 18, 2026	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jun 12, 2026	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
May 14, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
May 14, 2026	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Mar 30, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Jul 3, 2025	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Jun 10, 2024	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
May 24, 2024	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Jul 12, 2021	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jul 2, 2021	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Jan 15, 2021	S-1MEF →	REGISTERED	S-1MEF registration — capacity to sell shares, not a sale yet
Jan 15, 2021	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Jan 14, 2021	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jan 11, 2021	FWP →	MARKETING	Free-writing prospectus — offering being marketed
Jan 8, 2021	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Jun 17, 2020	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Jun 12, 2020	S-1MEF →	REGISTERED	S-1MEF registration — capacity to sell shares, not a sale yet
Jun 12, 2020	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Jun 10, 2020	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jun 8, 2020	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
May 19, 2020	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
May 19, 2020	FWP →	MARKETING	Free-writing prospectus — offering being marketed
May 12, 2020	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Apr 16, 2020	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet

LTRN offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full LTRN workspace →

LTRN offering FAQ

When did LTRN last execute an offering?

Per SEC filings, Lantern Pharma Inc.'s most recent priced offering document is a 424B5 filed 2026-05-14. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did LTRN last announce or register an offering?

The most recent registration is a S-1 filed 2026-06-12. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.